Clinical trials: Hair Problems, open to volunteers
Hair Thinning
Study Evaluating Xtressé Gummy Supplement in Women With Self-Perceived Thinning Hair
The goal of this study is to determine how safe and effective it is to improve hair growth using an active gummy treatment in women with self-perceived thinning hair. The main aims of this trial are: 1.
- Trial name
- NCT07224555
- Testing
- Xtressé Hair Growth Gummies
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Restore Biologics Holdings, Inc. dba Xtressé
Androgenetic Alopecia
Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia
The primary objective of this study is to evaluate the efficacy of once-daily 5% minoxidil foam versus placebo in female androgenetic alopecia, using the Target Area Terminal Hair Count (TAHC) as the primary endpoint.
- Trial name
- NCT07080931
- Testing
- 5% minoxidil foam
- Where
- China
- Volunteers
- 294 people
- Sponsor
- Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.
Alopecia Areata
Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata
The purpose of this study is to evaluate the safety and efficacy of NXC-736 monotherapy in participants with severe alopecia areata (AA).
- Trial name
- NCT06104839
- Testing
- NXC736
- Where
- 2 sites in South Korea
- Volunteers
- 73 people
- Sponsor
- NEXTGEN Bioscience
Alopecia Areata
A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.
This is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of FB102 in patients with severe to very severe alopecia areata (AA).
- Trial name
- NCT07205159
- Testing
- FB102
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 32 people
- Sponsor
- Forte Biosciences, Inc.
Androgenic Alopecia, Healthy Adult Male
Efficacy and Safety of Two Hair Supplements in Men With Androgenic Alopecia
The goal of this clinical trial is to evaluate the efficacy and safety of two different formulations of a food supplement on hair health in healthy Caucasian male subjects aged 35 to 65 years with mild to moderate androgenetic…
- Trial name
- NCT07806474
- Testing
- formulation of green tea leaf extract, bamboo shoot extract and selenium-enriched yeast, formulation of grape seed extract, bamboo shoot extract and selenium-enriched yeast
- Where
- 6 sites in Italy
- Volunteers
- 99 people
- Sponsor
- Activ'inside
Hair Loss/Baldness, Wrinkle Appearance
Autologous Adipose Cells Therapy
Autologous Adipose Cell Therapy is a series of process designated to address the demerits of the traditional autologous fat grafting and dermal fillers, while enhancing the versatility and aesthetic outcomes.
- Conditions
- Hair Loss/Baldness, Wrinkle Appearance, Volume, Fine Lines
- Trial name
- NCT06869252
- Testing
- Autologous Adipose Cells Therapy
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- CERM INC.
Severe Alopecia Areata
Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Severe Alopecia Areata Patients
The purpose of this study is to evaluate the efficacy and safety of different doses of SYHX1901 tablets in the treatment of severe alopecia areata.
- Trial name
- NCT06562894
- Testing
- SYHX1901
- Volunteers
- 156 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Alopecia Areata
A Study of LAD603 in Adults With Alopecia Areata
The main aim of the study is to evaluate the effect of LAD603 in adult participants with severe to very severe alopecia areata (AA).
- Trial name
- NCT07311564
- Testing
- LAD603
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Almirall, S.A.
Androgenetic Alopecia (AGA)
A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia
This study is designed to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of OLX72021 in medically healthy men with mild to moderate androgenetic alopecia.
- Trial name
- NCT07327359
- Testing
- OLX72021
- Where
- 8 sites in Australia, New Zealand
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Olix Pharmaceuticals, Inc.
Non-Segmental Vitiligo (NSV), Alopecia Areata
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
This study is to assess the burden of disease in adolescent and adult participants with moderate or severe alopecia areata (AA), non-segmental vitiligo (NSV), or moderate to severe hidradenitis suppurativa (HS) in a large global…
- Conditions
- Non-Segmental Vitiligo (NSV), Alopecia Areata, Hidradenitis Suppurativa
- Trial name
- MEASUREAAVitHS (NCT07136467)
- Where
- 116 sites in Argentina, Canada and 16 more
- Volunteers
- 2,795 people
- Sponsor
- AbbVie
Female Pattern Baldness
Efficacy and Safety of OMA102 in the Treatment of Female Pattern Hair Loss
The goal of this clinical trial is to evaluate the efficacy and safety of OMA102 1 mg and OMA102 2 mg versus placebo in the treatment of female pattern hair loss.
- Trial name
- GENERA (NCT05824065)
- Testing
- OMA102
- Where
- Brazil
- Volunteers
- 504 people
- Sponsor
- EMS
Areata Alopecia, Alopecia
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age.
- Conditions
- Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases
- Trial name
- BRAVE-AA-PEDS (NCT05723198)
- Testing
- Baricitinib
- Where
- 127 sites in United States, Argentina and 10 more
- Volunteers
- 595 people
- Sponsor
- Eli Lilly and Company
Androgenetic Alopecia (AGA)
To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia
This study is a multicenter, randomized, double-blind, vehicle controlled, adaptive design phase 2/3 study to evaluate the efficacy and safety of topical KX-826 solution in Chinese male patients with androgenetic alopecia (AGA).
- Trial name
- NCT06622824
- Testing
- KX-826 0.5% BID, KX-826 1.0% BID
- Where
- China
- Volunteers
- 756 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Androgenetic Alopecia, Androgenetic Alopecia (AGA)
Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia.
This study is a Phase 3 clinical trial designed to evaluate the efficacy and safety of N1087 compared with placebo in adult men with androgenetic alopecia (male pattern hair loss).
- Trial name
- MINORA-MEN (NCT07529977)
- Testing
- Minoxidil oral solution
- Volunteers
- 372 people
- Sponsor
- Eurofarma Laboratorios S.A.
Androgenetic Alopecia
Assessment of Dutasteride Topical Solution in Male Androgenetic Alopecia
This is a randomized, open-label phase 1/2a study designed to evaluate the pharmacokinetics, pharmacodynamics, and safety of AD-303A (topical formulation) and AD-3031 in male patients with androgenetic alopecia.
- Trial name
- NCT07490327
- Testing
- AD-303A, AD-3031
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Moogene Medi Co., Ltd
Androgenetic Alopecia
Phase 2 Efficacy and Safety of PP405 in Adult Females With Androgenetic Alopecia
The study is designed to evaluate safety and efficacy of PP405 in adult female participants with androgenetic alopecia
- Trial name
- AWAKENING (NCT07907783)
- Testing
- PP405 0.05% Topical Gel, Vehicle Topical Gel
- Volunteers
- 200 people
- Sponsor
- Pelage Pharmaceuticals, Inc.
Gut Dysbiosis, Telogen Effluvium
Gut Microbiota and Trichoscopic Changes in Women With Telogen Effluvium on a Multifactorial Drinkable Nutraceutical: A Retrospective Observational Study
Telogen effluvium (TE) is a common cause of diffuse, non-scarring hair shedding in women. It is often triggered by physiological stress, nutritional deficiencies, illness or hormonal changes.
- Conditions
- Gut Dysbiosis, Telogen Effluvium, Hair Loss
- Trial name
- NCT07869199
- Testing
- Drinkable multifactorial food supplement containing vitamins, minerals, plant extracts, and other bioactive compounds, formulated to support hair growth and scalp health in women.
- Where
- 2 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Olistic Research Labs S.L.
Androgenetic Alopecia
A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia
This is a multi-centers, randomized, double-blind, parallel-group, Phase 3 Trial to evaluate the efficacy and safety of CKD-843 in Male patients with Androgenetic Alopecia
- Trial name
- NCT06916793
- Testing
- CKD-843 dose#1, CKD-843 dose#2, Dutasteride Capsules
- Where
- South Korea
- Volunteers
- 288 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Vitiligo, Atopic Dermatitis
An Observational Study of Patients With Dermatologic Disease
TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients.
- Conditions
- Vitiligo, Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa (HS)
- Trial name
- TARGET-DERM+ (NCT07748169)
- Where
- United States
- Volunteers
- 2,000,000 people
- Sponsor
- Target PharmaSolutions, Inc.
Alopecia Areata
A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia Areata
This study is a multicenter, open-label, non-randomized, dose-finding Phase I study designed to evaluate the pharmacokinetics (PK), safety, and preliminary efficacy of VC005 tablets in adolescent subjects with severe alopecia…
- Trial name
- NCT07762443
- Testing
- VC005 tablets
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD